ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable development of acquired resistance limits its efficacy....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hongbo, Huang, Yutang, Shi, Jingjing, Dai, Yi, Wu, Lanxiang, Zhou, Honghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256088/
https://www.ncbi.nlm.nih.gov/pubmed/30515095
http://dx.doi.org/10.3389/fphar.2018.01312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256088/
https://www.ncbi.nlm.nih.gov/pubmed/30515095
http://dx.doi.org/10.3389/fphar.2018.01312

Ejemplares similares